India’s largest pharmaceutical company, Sun Pharmaceutical Industries Ltd, has announced the appointment of Kirti Ganorkar as its new Managing Director, effective September 1, 2025. This leadership transition marks a strategic shift as the company strengthens its global operations.
Key Highlights of the Leadership Change
- Ganorkar’s Role: He will oversee all business functions, ensuring continuity and growth.
- Dilip Shanghvi’s Position: The founder and outgoing MD will continue as Executive Chairman, focusing on Sun Pharma’s specialty portfolio.
- North America Leadership Shift: Richard Ascroft has been appointed as CEO of Sun Pharma’s North America business, succeeding Abhay Gandhi, who has resigned.
Ganorkar’s Contributions & Vision
- Industry Expertise: Ganorkar has been with Sun Pharma since 1996, leading India operations since 2019.
- Global Expansion: He played a key role in Sun Pharma’s entry into Japan and Europe, strengthening its international footprint.
- Strategic Growth: His leadership is expected to drive innovation, market expansion, and regulatory compliance.
Future Outlook
With Ganorkar at the helm, Sun Pharma aims to accelerate its specialty drug portfolio, expand global market share, and navigate evolving industry challenges.
For more updates on pharmaceutical industry trends, stay tuned! 🚀
